新型FAP抑制剂靶向诊疗用于碘难治性分化型甲状腺癌的初步研究
本探索性研究评估新型成纤维细胞活化蛋白抑制剂(FAP)靶向诊疗在酪氨酸激酶抑制剂治疗进展后的转移性碘难治性分化型甲状腺癌(RR-DTC)患者中的临床与安全性数据。患者接受[177Lu]Lu-DOTAGA.(SA.FAPi)2治疗,主要终点为甲状腺球蛋白(Tg)反应和功能影像反应。结果显示血清Tg显著下降,部分患者达部分缓解,疼痛与体能状态改善,未出现III/IV级血液、肾或肝毒性。
要点
- 新型FAP靶向放射性药物在RR-DTC中显示初步疗效与安全性。
- 治疗后血清Tg显著下降,部分患者达影像学部分缓解。
- 未观察到III/IV级血液、肾或肝毒性。
核心结论
- 新型分子[177Lu]Lu-DOTAGA.(SA.FAPi)2安全、似乎有效,为耗尽标准治疗的侵袭性RR-DTC患者开辟新途径。
主要发现
- 血清Tg中位数从基线10549 ng/mL(IQR 3066.5-39450)降至评估时5649 ng/mL(IQR 939.5-17099),p=0.0005。
- 分子反应评估无完全缓解,部分缓解4例,疾病稳定3例。
- VASmax评分从治疗前9(IQR 8-10)降至随访6(IQR 3-6),p<0.0001;ECOG体能状态从3(IQR 2-3)改善至2(IQR 2-3),p=0.0078。
- 共 administered 45个周期,中位累积给药活度8.2±2.7 GBq(范围5.5-14 GBq)。
- 全身有效剂量为1.62E-01±1.53E-02 mSv/MBq,结肠为关键器官。
关键数值与推荐
- 患者需[68Ga]Ga-DOTA.SA.FAPi PET/CT显示转移灶中等至优秀摄取并签署知情同意。
- [177Lu]Lu-DOTAGA.(SA.FAPi)2每八周静脉给药一次。
- 毒性分级采用CTCAE v5.0。
临床怎么用
- 对于TKIs治疗进展的RR-DTC患者,FAP靶向诊疗可能作为挽救治疗选择。
- 治疗前需通过[68Ga]Ga-DOTA.SA.FAPi PET/CT筛选摄取阳性的患者。
- 治疗期间需监测Tg、影像学反应及毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This exploratory study was meant to assess clinical and safety data with a novel fibroblast activation protein inhibitor-based targeted theranostics as a salvage treatment option in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients who had progressed on tyrosine kinase inhibitors. Methods: Patients with metastatic RR-DTC who progressed on sorafenib/lenvatinib were prospectively recruited. If [68Ga]Ga-DOTA.SA.FAPi positron emission tomography/computed tomography scan demonstrated moderate-to-excellent uptake in metastases, and patients had given informed consent, they received intravenous [177Lu]Lu-DOTAGA.(SA.FAPi)2 as therapy at eight-weekly intervals. The primary endpoints were thyroglobulin (Tg) response and functional imaging response. The secondary endpoints were visual analog score (VAS) and Eastern Cooperative Oncology Group (ECOG) performance status. The grading of toxicities was performed by using Common Terminology Criteria for Adverse Events (CTCAEV5.0). The sequential images were acquired by a dual-headed gamma camera, and dosimetric calculations were performed by using OLINDA/EXM V2.1. Results: Fifteen patients were recruited [age: 55 ± 9 years (range: 39-67)]. [177Lu]Lu-DOTAGA.(SA.FAPi)2 had median whole-body Teff of 88.06 hours (interquartile range [IQR]: 86.6-99). The colon was identified as a critical organ. The whole-body effective dose was 1.62E-01 ± 1.53E-02 mSv/MBq. A total of 45 cycles were administered, and the median cumulative administered activity was 8.2 ± 2.7 GBq (range 5.5-14 GBq). The median absorbed doses to the tumor lesions were 1.08E+01 (IQR: 4.16E+00 to 8.97E+01) mSv/MBq per cycle. The Serum Tg level significantly decreased after treatment [(median Tg: baseline-10,549 ng/mL (IQR: 3066.5-39,450) versus at the time of assessment: 5649 ng/mL (IQR: 939.5-17,099), p = 0.0005)]. Molecular response assessment revealed no complete response; however, partial response was documented in four, and stable disease in three patients. The VASmax scores [pre-therapy: 9 (IQR: 8-10) versus follow-up: 6 (3-6) (p-0.0001)], and ECOG [3, (IQR: 2-3 vs. 2, (IQR: 2-3) (p-0.0078)] performance scores significantly improved after treatment. None of the patients experienced grade III/IV hematological, renal, or hepatotoxicity. Conclusion: These preliminary data suggest that the novel molecule [177Lu]Lu-DOTAGA.(SA.FAPi)2 is safe, seems effective, and, most importantly, opens up a new avenue for the treatment of aggressive RR-DTC patients who have exhausted all standard line of treatments.
引用
- Ballal S, Yadav MP, Moon ES, et al. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid. 2021. PMID: 34641705. doi:10.1089/thy.2021.0412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。